Search Technologies

To improve the therapeutic effectiveness of PE-based immunotoxins through multiple rounds of drug administration, NIH inventors have sought to identify and remove the human B cell epitopes within PE. Previous work demonstrated that the removal of the murine B cell and T cell epitopes from PE reduced the immunogenicity of PE and resulted in immunotoxins with improved therapeutic activity. The National Cancer Institute's Laboratory of Molecular Biology seeks interested parties to co-develop and commercialize immunotoxins using toxin domains lacking human B cell epitopes.

The National Cancer Institute, Laboratory of Molecular Biology seeks parties to co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers.

Researchers at the National Cancer Institute have developed materials derived from polysaccharides that are capable of releasing nitric oxide into the surrounding environment. These materials could be incorporated into surgical dressings, cotton bandages, cellulose filters and dialysis membranes, or other medical devices

The National Cancer Institute seeks parties interested to license a method to generate RNA molecules suitable for nanoparticle and biomedical applications.

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.

The National Cancer Institute seeks parties interested in licensing a new class of small molecules for the treatment of prostate cancer.

The National Cancer Institute, Nanobiology Program seeks parties to co-develop cancer therapeutics base on antibody fragments.

Researchers at the NCI seek licensing and/or co-development research collaborations for an anti-viral polypeptide, Griffithsin, and its antiviral use against Hepatitis C, Severe Acute Respiratory Syndrome (SARS), H5N1, or Ebola.

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.